Clinical trials: Multisystem Atrophy
Progressive Supranuclear Palsy, Dementia With Lewy Bodies
In-Home Care for Patients With PSP and Related Disorders
Progressive Supranuclear Palsy and related disorders (PRD) are debilitating, costly, and understudied conditions. Improving access to comprehensive, specialized, in-home patient care offers the potential to minimize the downward…
- Conditions
- Progressive Supranuclear Palsy, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Syndrome
- Trial name
- NCT03552484
- Testing
- Home Visit Program, Usual Care/Online Survey
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Autonomic Nervous System Disorders, Pure Autonomic Failure
Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
Pharmacologic approaches to increase levels or actions of the vasodilatory peptide angiotensin-(1-7) are currently in development for the treatment of hypertension based on findings from animal models.
- Conditions
- Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
- Trial name
- NCT02591173
- Testing
- Angiotensin-(1-7), Saline
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt University Medical Center
Multiple System Atrophy, Dementia With Lewy Bodies (DLB)
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and…
- Conditions
- Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Trial name
- NCT07805967
- Testing
- We did not apply any interventions; only observational research was conducted.
- Where
- 20 sites in China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Multiple System Atrophy, MSA - Multiple System Atrophy
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Purpose of this phase 1 study is to assess the safety of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA)
- Trial name
- NCT05698017
- Testing
- hOMSC300
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Cytora Ltd.
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment.
- Trial name
- CYPRESS (NCT05696717)
- Testing
- Ampreloxetine
- Where
- 79 sites in United States, Argentina and 18 more
- Volunteers
- 102 people
- Sponsor
- Theravance Biopharma
Hypertension, Pure Autonomic Failure
Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension
Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing), and at least half of them also have high blood pressure while lying down (supine hypertension).
- Conditions
- Hypertension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
- Trial name
- NCT03042988
- Testing
- Heating pad
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH303 (NCT00738062)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 103 people
- Sponsor
- Chelsea Therapeutics
Orthostatic Hypotension, Pure Autonomic Failure
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
Compression garments have been shown to be effective in the treatment of orthostatic hypotension in autonomic failure patients. The purpose of this study is to determine the hemodynamic mechanisms by which abdominal compression…
- Conditions
- Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
- Trial name
- NCT02429557
- Testing
- Abdominal compression, midodrine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Vanderbilt University Medical Center
Multiple System Atrophy, Parkinson Disease
Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases
This is a non-interventional observational study designed to systematically record the results of routine laryngeal examinations and specific characteristics of dysphagia in patients with neurodegenerative disorders.
- Conditions
- Multiple System Atrophy, Parkinson Disease, Progressive Supranuclear Palsy, Motor Neuron Disease
- Trial name
- FEEMSA (NCT04706234)
- Where
- 16 sites in Austria, Germany and 6 more
- Volunteers
- 350 people
- Sponsor
- Kliniken Beelitz GmbH
Parkinson Disease, Multiple System Atrophy
Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime…
- Conditions
- Parkinson Disease, Multiple System Atrophy, REM Sleep Behavior Disorder, Pure Autonomic Failure
- Trial name
- NCT02640339
- Where
- United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Multiple System Atrophy
Natural History and Disease Progression Biomarkers of Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease characterised by a variable combination of parkinsonism, cerebellar impairment and autonomic dysfunction.
- Trial name
- ASPIRE-MSA (NCT04229173)
- Testing
- MRI acquisition, DAT-SPECT, blood sample, cerebrospinal fluid (optional)
- Where
- 10 sites in France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Multiple System Atrophy
A Study of TAK-341 in Treatment of Multiple System Atrophy
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).
- Trial name
- NCT05526391
- Testing
- TAK-341
- Where
- 41 sites in United States, Austria and 8 more
- Volunteers
- 158 people
- Sponsor
- Takeda
Multiple System Atrophy
Efficacy and Safety of Bilateral Cervical Lymphatic-Venous Anastomosis in the Treatment of Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare and aggressive neurodegenerative disorder characterized by a combination of motor impairments, autonomic dysfunction, and cerebellar ataxia, with no currently available disease-modifying…
- Trial name
- NCT07036939
- Testing
- Immediate LVA, Delayed LVA
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Multiple System Atrophy, MSA
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
- Trial name
- NCT02388295
- Testing
- AZD3241
- Where
- 17 sites in United States, Austria and 5 more
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Orthostatic Hypotension, Dysautonomic, Orthostatic Intolerance
The STAND-UP Study
Orthostatic hypotension (OH) and orthostatic intolerance (OI) are common conditions where blood pressure drops when standing up, causing dizziness, fainting, or fatigue.
- Trial name
- NCT07195903
- Testing
- Angioplasty or stenting
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- St. Francis Hospital, New York
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
This prospective observational study aims to identify and preliminarily validate molecular biomarkers, including microRNAs and metabolites, for the early differentiation of Parkinson's disease (PD) from atypical parkinsonian…
- Conditions
- PARKINSON DISEASE (Disorder), Atypical Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)
- Trial name
- BIOMARK-PS (NCT07604883)
- Where
- 2 sites in Poland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- International Institute of Molecular and Cell Biology in Warsaw
Post Acute COVID-19 Syndrome, Long COVID
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.
- Conditions
- Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent
- Trial name
- DSBLongCOVID (NCT05638620)
- Testing
- stellate ganglion block with 0.5% bupivacaine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonathann Kuo, MD
Shy-Drager Syndrome, Orthostatic Hypotension
Droxidopa in Treating Patients With Neurogenic Hypotension
Please note that the continuation study can be found at http://clinicaltrials.gov/show/NCT00633880. RATIONALE: Neurogenic hypotension is a fall in blood pressure that occurs when one moves from a lying down to a standing position…
- Trial name
- NCT00004478
- Testing
- droxidopa
- Where
- United States
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple System Atrophy, Parkinsonism
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
The prevalence of Multiple System Atrophy (MSA) is reported to be between 3.4 - 4.9 cases per 100,000 population. The estimated average incidence is 0.6 - 0.7 cases per 100,000 people per year.
- Conditions
- Multiple System Atrophy, Parkinsonism, Multiple System Atrophy, Parkinson Variant
- Trial name
- NCT04876326
- Testing
- Autologous Adipose Mesenchymal Stem Cell Implantation, Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation, Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- Universitas Indonesia
Parkinson Disease, Progressive Supranuclear Palsy
Speech Accessibility Project
The goal of the Speech Accessibility Project at the University of Illinois Beckman Institute (https://speechaccessibilityproject.beckman.illinois.edu) is to collect, annotate, and curate a shared database of speech samples from…
- Conditions
- Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Dementia With Lewy Bodies
- Trial name
- SAP (NCT05889260)
- Where
- 2 sites in United States
- Volunteers
- 485 people
- Sponsor
- University of Illinois at Urbana-Champaign